Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
2.

Heart Rate Variability Responses to an Undulating Resistance Training Program in Free-Living Conditions: A Case Study in a Collegiate Athlete.

Holmes CJ, Wind SA, Esco MR.

Sports (Basel). 2018 Oct 20;6(4). pii: E121. doi: 10.3390/sports6040121.

3.

The Stabilizing Influences of Linking Set Size and Model-Data Fit in Sparse Rater-Mediated Assessment Networks.

Wind SA, Jones E.

Educ Psychol Meas. 2018 Aug;78(4):679-707. doi: 10.1177/0013164417703733. Epub 2017 Apr 12.

PMID:
30147122
4.

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.

Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, Schlecker C, Moschetti V, Goetz S, Liesenfeld KH, Fillon G, Giovannini R, Ramael S, Wunderlich G, Wind S.

Clin Transl Sci. 2018 Nov;11(6):616-623. doi: 10.1111/cts.12578. Epub 2018 Aug 23.

5.

Emerging many-body effects in semiconductor artificial graphene with low disorder.

Du L, Wang S, Scarabelli D, Pfeiffer LN, West KW, Fallahi S, Gardner GC, Manfra MJ, Pellegrini V, Wind SJ, Pinczuk A.

Nat Commun. 2018 Aug 17;9(1):3299. doi: 10.1038/s41467-018-05775-4.

6.
7.

Incorporating Criterion Ratings Into Model-Based Rater Monitoring Procedures Using Latent-Class Signal Detection Theory.

Patterson BF, Wind SA, Engelhard G Jr.

Appl Psychol Meas. 2017 Sep;41(6):472-491. doi: 10.1177/0146621617698452. Epub 2017 Mar 27.

8.

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.

Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, Liesenfeld KH, Wunderlich G, Desch M.

Clin Drug Investig. 2018 Aug;38(8):737-750. doi: 10.1007/s40261-018-0660-2.

9.

Exploring Incomplete Rating Designs With Mokken Scale Analysis.

Wind SA, Patil YJ.

Educ Psychol Meas. 2018 Apr;78(2):319-342. doi: 10.1177/0013164416675393. Epub 2016 Oct 23.

PMID:
29795958
10.

Adjacent-Categories Mokken Models for Rater-Mediated Assessments.

Wind SA.

Educ Psychol Meas. 2017 Apr;77(2):330-350. doi: 10.1177/0013164416643826. Epub 2016 Apr 18.

11.

Full control of ligand positioning reveals spatial thresholds for T cell receptor triggering.

Cai H, Muller J, Depoil D, Mayya V, Sheetz MP, Dustin ML, Wind SJ.

Nat Nanotechnol. 2018 Jul;13(7):610-617. doi: 10.1038/s41565-018-0113-3. Epub 2018 Apr 30.

12.

Observation of Dirac bands in artificial graphene in small-period nanopatterned GaAs quantum wells.

Wang S, Scarabelli D, Du L, Kuznetsova YY, Pfeiffer LN, West KW, Gardner GC, Manfra MJ, Pellegrini V, Wind SJ, Pinczuk A.

Nat Nanotechnol. 2018 Jan;13(1):29-33. doi: 10.1038/s41565-017-0006-x. Epub 2017 Nov 27.

PMID:
29180741
13.

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.

Moschetti V, Desch M, Goetz S, Liesenfeld KH, Rosenbrock H, Kammerer KP, Wunderlich G, Wind S.

Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):239-249. doi: 10.1007/s13318-017-0440-z.

14.

Developing an Engineering Design Process Assessment using Mixed Methods.

Wind SA, Alemdar M, Lingle JA, Gale JD, Moore RA.

J Appl Meas. 2017;18(2):100-121.

PMID:
28961148
15.

The Functional Response of Mesenchymal Stem Cells to Electron-Beam Patterned Elastomeric Surfaces Presenting Micrometer to Nanoscale Heterogeneous Rigidity.

Biggs MJP, Fernandez M, Thomas D, Cooper R, Palma M, Liao J, Fazio T, Dahlberg C, Wheadon H, Pallipurath A, Pandit A, Kysar J, Wind SJ.

Adv Mater. 2017 Oct;29(39). doi: 10.1002/adma.201702119. Epub 2017 Sep 1.

PMID:
28861921
16.

Spatial Control of Biological Ligands on Surfaces Applied to T Cell Activation.

Cai H, Depoil D, Muller J, Sheetz MP, Dustin ML, Wind SJ.

Methods Mol Biol. 2017;1584:307-331. doi: 10.1007/978-1-4939-6881-7_18.

PMID:
28255709
17.
18.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL.

Ann Oncol. 2016 Nov;27(11):2103-2110. Epub 2016 Sep 6.

PMID:
27601237
19.

P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC.

Barrios CH, Wu YL, Chih-Hsin Yang J, Sequist LV, Geater SL, Mok T, Hu CP, Yamamoto N, O'Byrne K, Lu S, Hirsh V, Sebastian M, Okamoto I, Shah R, Märten A, Massey D, Wind S, Schuler M.

J Thorac Oncol. 2016 Oct;11(10S):S210-S211. doi: 10.1016/j.jtho.2016.08.067. Epub 2016 Sep 22. No abstract available.

20.

Improved Glass Surface Passivation for Single-Molecule Nanoarrays.

Cai H, Wind SJ.

Langmuir. 2016 Oct 4;32(39):10034-10041. Epub 2016 Sep 26.

21.

Exploring Rating Quality in Rater-Mediated Assessments Using Mokken Scale Analysis.

Wind SA, Engelhard G Jr.

Educ Psychol Meas. 2016 Aug;76(4):685-706. doi: 10.1177/0013164415604704. Epub 2015 Sep 17.

22.

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.

Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P.

Clin Pharmacokinet. 2017 Mar;56(3):235-250. doi: 10.1007/s40262-016-0440-1. Review.

23.

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.

Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S.

Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):461-469. doi: 10.1007/s13318-016-0359-9.

24.

Nanoscale Engineering of Closely-Spaced Electronic Spins in Diamond.

Scarabelli D, Trusheim M, Gaathon O, Englund D, Wind SJ.

Nano Lett. 2016 Aug 10;16(8):4982-90. doi: 10.1021/acs.nanolett.6b01692. Epub 2016 Jul 21.

PMID:
27428077
25.

Responsive Biomaterials: Advances in Materials Based on Shape-Memory Polymers.

Hardy JG, Palma M, Wind SJ, Biggs MJ.

Adv Mater. 2016 Jul;28(27):5717-24. doi: 10.1002/adma.201505417. Epub 2016 Apr 27.

PMID:
27120512
26.

Molecular Occupancy of Nanodot Arrays.

Cai H, Wolfenson H, Depoil D, Dustin ML, Sheetz MP, Wind SJ.

ACS Nano. 2016 Apr 26;10(4):4173-83. doi: 10.1021/acsnano.5b07425. Epub 2016 Mar 15.

27.

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, Pelling K, Wind S, Bousquet G, Misset JL.

Springerplus. 2016 Jan 19;5:45. doi: 10.1186/s40064-015-1601-7. eCollection 2016.

28.

Directed Assembly of Single Wall Carbon Nanotube Field Effect Transistors.

Penzo E, Palma M, Chenet DA, Ao G, Zheng M, Hone JC, Wind SJ.

ACS Nano. 2016 Feb 23;10(2):2975-81. doi: 10.1021/acsnano.6b00353. Epub 2016 Feb 1.

PMID:
26807948
29.

Advances in Functional Assemblies for Regenerative Medicine.

Palma M, Hardy JG, Tadayyon G, Farsari M, Wind SJ, Biggs MJ.

Adv Healthc Mater. 2015 Nov 18;4(16):2500-19. doi: 10.1002/adhm.201500412. Review.

PMID:
26767738
30.

Control of DNA origami inter-tile connection with vertical linkers.

Wang R, Gorday K, Nuckolls C, Wind SJ.

Chem Commun (Camb). 2016 Jan 28;52(8):1610-3. doi: 10.1039/c5cc08185h. Epub 2015 Dec 11.

PMID:
26662034
31.

Directed Assembly of End-Functionalized Single Wall Carbon Nanotube Segments.

Penzo E, Palma M, Wang R, Cai H, Zheng M, Wind SJ.

Nano Lett. 2015 Oct 14;15(10):6547-52. doi: 10.1021/acs.nanolett.5b02220. Epub 2015 Sep 9.

PMID:
26340414
32.

Classroom ventilation and indoor air quality-results from the FRESH intervention study.

Rosbach J, Krop E, Vonk M, van Ginkel J, Meliefste C, de Wind S, Gehring U, Brunekreef B.

Indoor Air. 2016 Aug;26(4):538-45. doi: 10.1111/ina.12231. Epub 2015 Aug 4.

PMID:
26171647
33.

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM.

Future Oncol. 2015;11(10):1479-91. doi: 10.2217/fon.15.50.

PMID:
25963426
34.
35.

Long-range charge transport in single G-quadruplex DNA molecules.

Livshits GI, Stern A, Rotem D, Borovok N, Eidelshtein G, Migliore A, Penzo E, Wind SJ, Di Felice R, Skourtis SS, Cuevas JC, Gurevich L, Kotlyar AB, Porath D.

Nat Nanotechnol. 2014 Dec;9(12):1040-6. doi: 10.1038/nnano.2014.246. Epub 2014 Oct 26.

PMID:
25344689
36.

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium.

Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19.

37.
38.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R.

Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7.

39.

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.

Freiwald M, Schmid U, Fleury A, Wind S, Stopfer P, Staab A.

Cancer Chemother Pharmacol. 2014 Apr;73(4):759-70. doi: 10.1007/s00280-014-2403-2. Epub 2014 Feb 13.

PMID:
24522402
40.

Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.

Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P.

Clin Drug Investig. 2014 Mar;34(3):173-82. doi: 10.1007/s40261-013-0161-2.

PMID:
24399452
41.

Bifunctional nanoarrays for probing the immune response at the single-molecule level.

Cai H, Depoil D, Palma M, Sheetz MP, Dustin ML, Wind SJ.

J Vac Sci Technol B Nanotechnol Microelectron. 2013 Nov;31(6):6F902. Epub 2013 Oct 8.

42.

Robustly passivated, gold nanoaperture arrays for single-molecule fluorescence microscopy.

Kinz-Thompson CD, Palma M, Pulukkunat DK, Chenet D, Hone J, Wind SJ, Gonzalez RL Jr.

ACS Nano. 2013 Sep 24;7(9):8158-66. doi: 10.1021/nn403447s. Epub 2013 Sep 6.

43.

Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.

Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P.

Clin Pharmacokinet. 2013 Dec;52(12):1101-9. doi: 10.1007/s40262-013-0091-4.

PMID:
23813493
44.

Controlled formation of carbon nanotube junctions via linker-induced assembly in aqueous solution.

Palma M, Wang W, Penzo E, Brathwaite J, Zheng M, Hone J, Nuckolls C, Wind SJ.

J Am Chem Soc. 2013 Jun 12;135(23):8440-3. doi: 10.1021/ja4018072. Epub 2013 May 29.

PMID:
23656193
45.

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.

Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels JP.

Ann Oncol. 2013 May;24(5):1392-400. doi: 10.1093/annonc/mds633. Epub 2013 Jan 4.

PMID:
23293114
46.

Examining rating quality in writing assessment: rater agreement, error, and accuracy.

Wind SA, Engelhard G Jr.

J Appl Meas. 2012;13(4):321-35.

PMID:
23270978
47.

Endotoxin levels in homes and classrooms of Dutch school children and respiratory health.

Jacobs JH, Krop EJ, de Wind S, Spithoven J, Heederik DJ.

Eur Respir J. 2013 Aug;42(2):314-22. doi: 10.1183/09031936.00084612. Epub 2012 Oct 25.

48.

Assembly of heterogeneous functional nanomaterials on DNA origami scaffolds.

Wang R, Nuckolls C, Wind SJ.

Angew Chem Int Ed Engl. 2012 Nov 5;51(45):11325-7. doi: 10.1002/anie.201206389. Epub 2012 Oct 10.

49.

Single-molecule imaging reveals target-search mechanisms during DNA mismatch repair.

Gorman J, Wang F, Redding S, Plys AJ, Fazio T, Wind S, Alani EE, Greene EC.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3074-83. doi: 10.1073/pnas.1211364109. Epub 2012 Sep 24.

50.

Measuring intermolecular rupture forces with a combined TIRF-optical trap microscope and DNA curtains.

Lee JY, Wang F, Fazio T, Wind S, Greene EC.

Biochem Biophys Res Commun. 2012 Oct 5;426(4):565-70. doi: 10.1016/j.bbrc.2012.08.127. Epub 2012 Sep 4.

Supplemental Content

Support Center